Developer docs
API playgroundTry for free, no card

Search company profiles

Somnics

Full company profile

uuid000fcdg

Namestring
Somnics
Legal namestring
萊鎂醫療器材股份有限公司
Websiteurl
somnics.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Somnics Inc. (萊鎂醫療器材股份有限公司) is a Taiwan-based, Taiwan OTC-listed (stock code 6633) medical device company founded in 2011 that researches, develops, manufactures, and commercializes sleep therapy systems for obstructive sleep apnea (OSA). Its flagship iNAP Sleep Therapy System applies gentle intraoral negative pressure via a small mouth-console to stabilize the tongue, soft palate, and surrounding tissues, keeping the upper airway open during sleep without masks, hoses, belts, or forced air; the system is battery-powered, pocket-sized, and silent during operation. The product family includes iNAP One, iNAP Lite (NP-R03-K), ZEEBUD, iBreath, and the iNAP Lab+ companion app that streams sleep data to a cloud platform for clinician titration and remote monitoring.

Somnics generates revenue through sales of the iNAP console and recurring oral-interface consumables to healthcare institutions and patients; the June 2025 launch of iNAP Essentials — a $58/month, 24-month subscription bundling device, supplies, coaching, and app access — introduces a direct-to-consumer recurring model. Two adjacent revenue streams exist: Taiwan distribution of the Lucira Check It COVID-19 test kit through pharmacy chains at NT$1,890 per unit, and IVD contract manufacturing for Maxnerva Technology Services leveraging the company's ISO 7/Class 10,000 cleanroom.

The company goes to market through a hybrid model: enterprise and clinical marketing at respiratory and sleep conferences (ATS, ERS, DGSM, Sleep DownUnder), an exclusive U.S. federal channel via First Nation Group under Federal Supply Schedule contract #36F79719D0027 (already deployed in 36+ VA Medical Centers, targeting ~172 VA sleep centers), exclusive international distribution through LMT Korea in South Korea, retail pharmacy networks in Taiwan, and now a U.S. direct-to-consumer subscription channel. Regulatory clearances include FDA 510(k) (K193460, May 2020), EU CE Mark under MDD 93/42/EEC, Taiwan TFDA, Australia TGA, Hong Kong MDCO, Israel MOH, Malaysia MDA, Singapore HSA, Thailand TFDA MDCD, Vietnam DMEHW, and South Korea MFDS GMP. The company's IP portfolio (162 granted patents and 30 registered trademarks as of 2021) covers the negative pressure mechanism across the U.S., EU, Japan, Korea, China, Australia, and Southeast Asia.

Short descriptiontext

Somnics is a Taiwan-based medical device company (Taiwan OTC: 6633) that develops the iNAP Sleep Therapy System, a mask-free intraoral negative pressure device for treating obstructive sleep apnea, sold globally to the U.S. VA healthcare system, sleep clinics, and CPAP-intolerant patients across roughly a dozen countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHsinchu, Taiwan
HQ citystring
Hsinchu
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sleep apnea therapy, negative pressure medical devices, OSA treatment, intraoral sleep devices, respiratory care equipment
Industry3 codes
PRIMARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAFAEAF
Home Respiratory & Sleep Therapy Providers (DME-Integrated)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sleep Apnea Therapy Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1iNAP Sleep Therapy System (device + consumables)
TypeHardware Sales
Description

Sale of the iNAP console and oral interface consumables to patients and healthcare institutions. Revenue from device sales and repeat consumable purchases (e.g., oral interface accessories).

somnics.com
2iNAP Essentials Subscription Program
TypeSubscription Recurring
Description

Monthly subscription at $58/month over 24 months, including full starter kit, supplies, coaching, and app integration — a recurring revenue model bundled with the device and support services.

businesswire.com
3Lucira COVID-19 Test Kit Distribution
TypeTransaction Fee
Description

Distribution of Lucira Check It COVID-19 Test Kit in Taiwan at NT$1,890 per unit, generating one-time transaction revenue through pharmacy and retail channels.

somnics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1iNAP Essentials subscription covering device, consumables, coaching, and app — $58/month over 24 months
ModelSubscriptionBilling cadenceMonthly
Notes

Full starter kit, supplies, coaching, and iNAP Lab+ app integration included. Total cost over 24 months: $1,392.

businesswire.com
2Lucira Check It COVID-19 Test Kit at NT$1,890 per unit (one-time purchase)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Sold at pharmacies and retail outlets in Taiwan (Da Shu, Ding Ding, Quanbao, Heping Pharmacy, Xinpu Pharmacy).

somnics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1iNAP
Description

iNAP Sleep Therapy System - negative pressure device for treating Obstructive Sleep Apnea (OSA). Features include natural breathing through nose, mask-free operation, compact portable design, and quiet operation.

somnics.com
+2 more records
Core offering1 text field

Somnics researches, develops, manufactures, and commercializes the iNAP Sleep Therapy System — a battery-powered intraoral negative pressure medical device that treats Obstructive Sleep Apnea (OSA) by stabilizing the tongue and soft palate through gentle oral suction, allowing natural nasal breathing without masks, hoses, or surgery. The portfolio spans iNAP One and iNAP Lite hardware variants, ZEEBUD and iBreath sub-brand products, the iNAP Lab+ cloud-monitoring companion app, and an iNAP Essentials subscription program for U.S. patients. The company also distributes the Lucira Check It COVID-19 Test Kit in Taiwan through pharmacy and retail channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Adjustable intraoral negative pressure therapy significantly improves treatment success rates and sleep quality for OSA patients (Sleep and Breathing journal, 2021)
+1 more record
Product overview1 text field

Somnics offers a portfolio of medical devices for treating Obstructive Sleep Apnea (OSA) centered on the iNAP Sleep Therapy System, which uses innovative negative pressure technology to maintain airway patency during sleep. The core iNAP platform includes multiple models (iNAP One, iNAP Lite) and is complemented by companion products ZEEBUD and iBreath. The ecosystem includes the iNAP Lab+ app for patient monitoring and the iNAP Essentials subscription program for affordable access. Somnics also distributed the Lucira COVID-19 nucleic acid test kit (萊析樂) in Taiwan as a separate product line.

Product and service7 records
1iNAP Sleep Therapy System
CategorySleep Apnea Therapy Devices
Description

A battery-powered intraoral negative pressure medical device for treating Obstructive Sleep Apnea (OSA). It uses gentle suction to pull the tongue, soft palate, and surrounding soft tissues forward to maintain airway patency during sleep, enabling natural nasal breathing without masks, hoses, or forced air. Sold to VA Medical Centers, sleep clinics, and ENT physicians globally.

2iNAP One Sleep Therapy System
CategorySleep Apnea Therapy Devices
Description

An advanced version of the iNAP system offering precision therapy for OSA, available in multiple oral interface sizes with thermal-memory material and iNAP Lab+ app compatibility for cloud-based sleep monitoring. FDA 510(k)-cleared and listed on the U.S. Federal Supply Schedule for the VA healthcare system.

3iNAP Lite (NP-R03-K)
CategorySleep Apnea Therapy Devices
Description

A compact variant of the iNAP Sleep Therapy System, with Taiwan TFDA and Hong Kong registration, intended for treating Obstructive Sleep Apnea.

4ZEEBUD
CategorySleep Therapy Devices
Description

A product in Somnics' sleep therapy portfolio, sold under the ZEEBUD sub-brand. Specific product details are limited in the source materials.

5iBreath
CategorySleep Therapy Devices
Description

A product in Somnics' portfolio sold under the iBreath sub-brand. Specific product details are limited in the source materials.

6iNAP Essentials Subscription Program
CategoryDirect-to-Consumer Subscription Programs
Description

A monthly subscription program ($58/month over 24 months) that delivers the iNAP Sleep Therapy System directly to U.S. consumers, bundling a full starter kit, ongoing supplies, coaching, and iNAP Lab+ app integration to improve affordability and access to mask-free OSA therapy.

7Lucira Check It COVID-19 Test Kit (Taiwan distribution)
CategoryIn-Vitro Diagnostics Distribution
Description

Distribution of the Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized) in Taiwan at NT$1,890 per unit through pharmacy and retail chains (Da Shu, Ding Ding, Quanbao, Heping, Xinpu, and PX Mart).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Lucira Health, Inc.
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-09
Description

Taiwan regional distributor for Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized). Lucira granted Somnics exclusive overseas distribution rights. Product sold at NT$1,890 per unit through pharmacies and retail chains in Taiwan.

somnics.com
2雲智匯科技服務 (Maxnerva Technology Services)
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-03-19
Description

Strategic partnership where Somnics provides IVD product engineering development and professional manufacturing services to Maxnerva, leveraging Somnics' QMS, ISO 7/Class 10,000 cleanroom, and medical device manufacturing expertise. Expands Somnics' production capacity and capabilities into IVD contract manufacturing.

somnics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Exclusive partnership for U.S. federal healthcare (VA system) distribution of iNAP One via Federal Supply Schedule (Contract #36F79719D0027). First Nation Group provides remote setup and patient support services. Enables procurement across the VA healthcare system, covering 36+ existing VA Medical Centers and expansion to nearly 172 VA sleep centers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

Exclusive South Korean distributor for iNAP. LMT Korea is the largest CPAP provider in South Korea, operating LÖWENSTEIN Academy (sleep training center) and serving over 200 medical institutions. Somnics obtained MFDS GMP certification in 2021, and product registration expected in Q3 2021. Partnership targets the estimated 1 in 5 South Koreans affected by OSA.

5國立中央大學 (National Central University) — Prof. Lo Meng-zong and Prof. Lin Cheng
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Co-development of the remote multi-physiological analysis platform system with National Central University. The cloud platform provides remote medical care services, combining Somnics' patented negative pressure sleep therapy device with cloud-based physiological data analysis. Won the 2020 Medication Technology R&D Bronze Award.

somnics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in CPAP and OSA therapy devices with multi-billion-dollar revenue, extensive physician relationships, and deep payer reimbursement infrastructure. Direct competitor in the OSA therapy market but serves as the entrenched standard-of-care that iNAP positions against as a mask-free alternative.

TypeDirect peer
Description

Developer of an implantable hypoglossal nerve stimulation system for OSA as a CPAP alternative. Most directly comparable as an alternative OSA therapy targeting CPAP-intolerant patients with FDA-cleared, novel-mechanism devices. Listed on NYSE with established U.S. commercial infrastructure.

3Oventus Medical
TypeEmerging player
Description

Australian developer of oral appliance and novel airway devices for OSA treatment targeting CPAP-intolerant patients. Comparable as an emerging alternative OSA therapy company with a different mechanism (oral appliance) but similar patient segment and clinical positioning.

TypeDirect peer
Description

Chinese manufacturer of CPAP, BiPAP, and respiratory care devices with significant Asia-Pacific and emerging market distribution. Comparable to Somnics as an OSA device manufacturer targeting similar patient populations with mask-based positive pressure therapy.

5Apex Medical
TypeDirect peer
Description

Taiwanese medical device company manufacturing CPAP, BiPAP, and respiratory therapy products with strong Asia-Pacific presence. Closely comparable as a Taiwan-based OSA device peer competing in overlapping markets with similar hospital and homecare channels.

TypeEmerging player
Description

Provider of sleep diagnostics and neurological monitoring equipment used in sleep labs and home testing. Adjacent peer in the broader sleep medicine ecosystem with comparable clinical customers (sleep specialists, sleep centers) but focused on diagnostics rather than therapy.

TypeBroad incumbent
Description

Major incumbent in CPAP, BiPAP, and OSA therapy devices with broad hospital and homecare distribution. Despite recent CPAP recall challenges, remains one of the largest OSA therapy device providers globally and a key competitive benchmark for Somnics' market entry.

TypeBroad incumbent
Description

New Zealand-based manufacturer of CPAP devices, humidifiers, and respiratory care products with strong presence in OSA and hospital respiratory markets. Competes in the same sleep apnea therapy category with a broader respiratory portfolio.

TypeEmerging player
Description

Israeli company (acquired by ZOLL Medical) developing home sleep apnea diagnostics and WatchPAT devices. Comparable as an Israel-based sleep medicine company with similar regulatory footprint and clinical focus on OSA diagnosis and management pathways.

TypeRegional player
Description

German respiratory and sleep therapy equipment manufacturer with established Korean distribution through LMT Korea (Somnics' exclusive Korean partner). Comparable as a CPAP and OSA therapy competitor with similar products in Somnics' distribution markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Somnics

Sleep Apnea Therapy Medical Devicessomnics.com

Somnics is a Taiwan-based medical device company (Taiwan OTC: 6633) that develops the iNAP Sleep Therapy System, a mask-free intraoral negative pressure device for treating obstructive sleep apnea, sold globally to the U.S. VA healthcare system, sleep clinics, and CPAP-intolerant patients across roughly a dozen countries.

What Somnics does

Somnics Inc. (萊鎂醫療器材股份有限公司) is a Taiwan-based, Taiwan OTC-listed (stock code 6633) medical device company founded in 2011 that researches, develops, manufactures, and commercializes sleep therapy systems for obstructive sleep apnea (OSA). Its flagship iNAP Sleep Therapy System applies gentle intraoral negative pressure via a small mouth-console to stabilize the tongue, soft palate, and surrounding tissues, keeping the upper airway open during sleep without masks, hoses, belts, or forced air; the system is battery-powered, pocket-sized, and silent during operation. The product family includes iNAP One, iNAP Lite (NP-R03-K), ZEEBUD, iBreath, and the iNAP Lab+ companion app that streams sleep data to a cloud platform for clinician titration and remote monitoring.

Somnics generates revenue through sales of the iNAP console and recurring oral-interface consumables to healthcare institutions and patients; the June 2025 launch of iNAP Essentials — a $58/month, 24-month subscription bundling device, supplies, coaching, and app access — introduces a direct-to-consumer recurring model. Two adjacent revenue streams exist: Taiwan distribution of the Lucira Check It COVID-19 test kit through pharmacy chains at NT$1,890 per unit, and IVD contract manufacturing for Maxnerva Technology Services leveraging the company's ISO 7/Class 10,000 cleanroom.

The company goes to market through a hybrid model: enterprise and clinical marketing at respiratory and sleep conferences (ATS, ERS, DGSM, Sleep DownUnder), an exclusive U.S. federal channel via First Nation Group under Federal Supply Schedule contract #36F79719D0027 (already deployed in 36+ VA Medical Centers, targeting ~172 VA sleep centers), exclusive international distribution through LMT Korea in South Korea, retail pharmacy networks in Taiwan, and now a U.S. direct-to-consumer subscription channel. Regulatory clearances include FDA 510(k) (K193460, May 2020), EU CE Mark under MDD 93/42/EEC, Taiwan TFDA, Australia TGA, Hong Kong MDCO, Israel MOH, Malaysia MDA, Singapore HSA, Thailand TFDA MDCD, Vietnam DMEHW, and South Korea MFDS GMP. The company's IP portfolio (162 granted patents and 30 registered trademarks as of 2021) covers the negative pressure mechanism across the U.S., EU, Japan, Korea, China, Australia, and Southeast Asia.

Somnics firmographics

Firmographics
Name
Somnics
Legal name
萊鎂醫療器材股份有限公司
Website
https://somnics.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Somnics is a Taiwan-based medical device company (Taiwan OTC: 6633) that develops the iNAP Sleep Therapy System, a mask-free intraoral negative pressure device for treating obstructive sleep apnea, sold globally to the U.S. VA healthcare system, sleep clinics, and CPAP-intolerant patients across roughly a dozen countries.
Ownership category
akta.pro rank

Somnics industry classification

Industry
Product category
Sleep Apnea Therapy Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAFAEAF
Home Respiratory & Sleep Therapy Providers (DME-Integrated)

Keywords

  • Sleep apnea therapy
  • Negative pressure medical devices
  • OSA treatment
  • Intraoral sleep devices
  • Respiratory care equipment

Where Somnics is headquartered

Location

Headquarters

HQ city
Hsinchu
HQ country
Taiwan
HQ region
Asia

Offices2 records

Markets served

Somnics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. iNAP Sleep Therapy System (device + consumables): Sale of the iNAP console and oral interface consumables to patients and healthcare institutions. Revenue from device sales and repeat consumable purchases (e.g., oral interface accessories).
  2. iNAP Essentials Subscription Program: Monthly subscription at $58/month over 24 months, including full starter kit, supplies, coaching, and app integration — a recurring revenue model bundled with the device and support services.
  3. Lucira COVID-19 Test Kit Distribution: Distribution of Lucira Check It COVID-19 Test Kit in Taiwan at NT$1,890 per unit, generating one-time transaction revenue through pharmacy and retail channels.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyiNAP Essentials subscription covering device, consumables, coaching, and app — $58/month over 24 months
Unit PricingPay-as-you-goLucira Check It COVID-19 Test Kit at NT$1,890 per unit (one-time purchase)

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Somnics product offering

Product offering

Core offering

Somnics researches, develops, manufactures, and commercializes the iNAP Sleep Therapy System — a battery-powered intraoral negative pressure medical device that treats Obstructive Sleep Apnea (OSA) by stabilizing the tongue and soft palate through gentle oral suction, allowing natural nasal breathing without masks, hoses, or surgery. The portfolio spans iNAP One and iNAP Lite hardware variants, ZEEBUD and iBreath sub-brand products, the iNAP Lab+ cloud-monitoring companion app, and an iNAP Essentials subscription program for U.S. patients. The company also distributes the Lucira Check It COVID-19 Test Kit in Taiwan through pharmacy and retail channels.

Product overview

Somnics offers a portfolio of medical devices for treating Obstructive Sleep Apnea (OSA) centered on the iNAP Sleep Therapy System, which uses innovative negative pressure technology to maintain airway patency during sleep. The core iNAP platform includes multiple models (iNAP One, iNAP Lite) and is complemented by companion products ZEEBUD and iBreath. The ecosystem includes the iNAP Lab+ app for patient monitoring and the iNAP Essentials subscription program for affordable access. Somnics also distributed the Lucira COVID-19 nucleic acid test kit (萊析樂) in Taiwan as a separate product line.

Differentiator

Problem solved

Functional benefit

Brands

  • iNAP: iNAP Sleep Therapy System - negative pressure device for treating Obstructive Sleep Apnea (OSA). Features include natural breathing through nose, mask-free operation, compact portable design, and quiet operation.
  • ZEEBUD
  • iBreath

Products and services

  • iNAP Sleep Therapy System A battery-powered intraoral negative pressure medical device for treating Obstructive Sleep Apnea (OSA). It uses gentle suction to pull the tongue, soft palate, and surrounding soft tissues forward to maintain airway patency during sleep, enabling natural nasal breathing without masks, hoses, or forced air. Sold to VA Medical Centers, sleep clinics, and ENT physicians globally.
  • iNAP One Sleep Therapy System An advanced version of the iNAP system offering precision therapy for OSA, available in multiple oral interface sizes with thermal-memory material and iNAP Lab+ app compatibility for cloud-based sleep monitoring. FDA 510(k)-cleared and listed on the U.S. Federal Supply Schedule for the VA healthcare system.
  • iNAP Lite (NP-R03-K) A compact variant of the iNAP Sleep Therapy System, with Taiwan TFDA and Hong Kong registration, intended for treating Obstructive Sleep Apnea.
  • ZEEBUD A product in Somnics' sleep therapy portfolio, sold under the ZEEBUD sub-brand. Specific product details are limited in the source materials.
  • iBreath A product in Somnics' portfolio sold under the iBreath sub-brand. Specific product details are limited in the source materials.
  • iNAP Essentials Subscription Program A monthly subscription program ($58/month over 24 months) that delivers the iNAP Sleep Therapy System directly to U.S. consumers, bundling a full starter kit, ongoing supplies, coaching, and iNAP Lab+ app integration to improve affordability and access to mask-free OSA therapy.
  • Lucira Check It COVID-19 Test Kit (Taiwan distribution) Distribution of the Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized) in Taiwan at NT$1,890 per unit through pharmacy and retail chains (Da Shu, Ding Ding, Quanbao, Heping, Xinpu, and PX Mart).

Quantifiable outcome

  • Adjustable intraoral negative pressure therapy significantly improves treatment success rates and sleep quality for OSA patients (Sleep and Breathing journal, 2021)
  • +1 more outcomes

Companies that use Somnics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Somnics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Somnics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Lucira Health, Inc.minorChannel Partner/ Reseller/ Distributor · 9 July 2021Taiwan regional distributor for Lucira Check It COVID-19 Test Kit (RT-LAMP molecular amplification technology, FDA EUA authorized). Lucira granted Somnics exclusive overseas distribution rights. Product sold at NT$1,890 per unit through pharmacies and retail chains in Taiwan.
  • 雲智匯科技服務 (Maxnerva Technology Services)minorImplementation/ SI/ Consulting Partner · 19 March 2021Strategic partnership where Somnics provides IVD product engineering development and professional manufacturing services to Maxnerva, leveraging Somnics' QMS, ISO 7/Class 10,000 cleanroom, and medical device manufacturing expertise. Expands Somnics' production capacity and capabilities into IVD contract manufacturing.
  • First Nation GroupcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Exclusive partnership for U.S. federal healthcare (VA system) distribution of iNAP One via Federal Supply Schedule (Contract #36F79719D0027). First Nation Group provides remote setup and patient support services. Enables procurement across the VA healthcare system, covering 36+ existing VA Medical Centers and expansion to nearly 172 VA sleep centers.
  • LMT Korea Co., LtdcoreChannel Partner/ Reseller/ Distributor · 1 January 2020Exclusive South Korean distributor for iNAP. LMT Korea is the largest CPAP provider in South Korea, operating LÖWENSTEIN Academy (sleep training center) and serving over 200 medical institutions. Somnics obtained MFDS GMP certification in 2021, and product registration expected in Q3 2021. Partnership targets the estimated 1 in 5 South Koreans affected by OSA.
  • 國立中央大學 (National Central University) — Prof. Lo Meng-zong and Prof. Lin ChengminorStrategic or Co-development Partner · 1 January 2020Co-development of the remote multi-physiological analysis platform system with National Central University. The cloud platform provides remote medical care services, combining Somnics' patented negative pressure sleep therapy device with cloud-based physiological data analysis. Won the 2020 Medication Technology R&D Bronze Award.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Somnics competitors and assessment

Company assessment

Broad incumbents

  • ResMed: Global leader in CPAP and OSA therapy devices with multi-billion-dollar revenue, extensive physician relationships, and deep payer reimbursement infrastructure. Direct competitor in the OSA therapy market but serves as the entrenched standard-of-care that iNAP positions against as a mask-free alternative.
  • Philips Respironics: Major incumbent in CPAP, BiPAP, and OSA therapy devices with broad hospital and homecare distribution. Despite recent CPAP recall challenges, remains one of the largest OSA therapy device providers globally and a key competitive benchmark for Somnics' market entry.
  • Fisher & Paykel Healthcare: New Zealand-based manufacturer of CPAP devices, humidifiers, and respiratory care products with strong presence in OSA and hospital respiratory markets. Competes in the same sleep apnea therapy category with a broader respiratory portfolio.

Direct peers

  • Inspire Medical Systems: Developer of an implantable hypoglossal nerve stimulation system for OSA as a CPAP alternative. Most directly comparable as an alternative OSA therapy targeting CPAP-intolerant patients with FDA-cleared, novel-mechanism devices. Listed on NYSE with established U.S. commercial infrastructure.
  • BMC Medical: Chinese manufacturer of CPAP, BiPAP, and respiratory care devices with significant Asia-Pacific and emerging market distribution. Comparable to Somnics as an OSA device manufacturer targeting similar patient populations with mask-based positive pressure therapy.
  • Apex Medical: Taiwanese medical device company manufacturing CPAP, BiPAP, and respiratory therapy products with strong Asia-Pacific presence. Closely comparable as a Taiwan-based OSA device peer competing in overlapping markets with similar hospital and homecare channels.

Emerging players

  • Oventus Medical: Australian developer of oral appliance and novel airway devices for OSA treatment targeting CPAP-intolerant patients. Comparable as an emerging alternative OSA therapy company with a different mechanism (oral appliance) but similar patient segment and clinical positioning.
  • Natus Medical: Provider of sleep diagnostics and neurological monitoring equipment used in sleep labs and home testing. Adjacent peer in the broader sleep medicine ecosystem with comparable clinical customers (sleep specialists, sleep centers) but focused on diagnostics rather than therapy.
  • Itamar Medical: Israeli company (acquired by ZOLL Medical) developing home sleep apnea diagnostics and WatchPAT devices. Comparable as an Israel-based sleep medicine company with similar regulatory footprint and clinical focus on OSA diagnosis and management pathways.

Regional players

  • Löwenstein Medical (LMT Korea partner): German respiratory and sleep therapy equipment manufacturer with established Korean distribution through LMT Korea (Somnics' exclusive Korean partner). Comparable as a CPAP and OSA therapy competitor with similar products in Somnics' distribution markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Somnics social profiles

Digital presence

Somnics compliance and trust

Trust signal

Compliance8 records

Somnics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Somnics leadership team

Management profile

Number of profiles

Profiles5 records

Somnics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Somnics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Somnics

What does Somnics do?

Somnics researches, develops, manufactures, and commercializes the iNAP Sleep Therapy System — a battery-powered intraoral negative pressure medical device that treats Obstructive Sleep Apnea (OSA) by stabilizing the tongue and soft palate through gentle oral suction, allowing natural nasal breathing without masks, hoses, or surgery. The portfolio spans iNAP One and iNAP Lite hardware variants, ZEEBUD and iBreath sub-brand products, the iNAP Lab+ cloud-monitoring companion app, and an iNAP Essentials subscription program for U.S. patients. The company also distributes the Lucira Check It COVID-19 Test Kit in Taiwan through pharmacy and retail channels.

Is Somnics a public or private company?

Somnics is a public company. It is classified as public and is currently operating.

When was Somnics founded?

Somnics was founded in 2011. It employs 11 to 50 people.

Where is Somnics based?

Somnics is headquartered in Hsinchu, Taiwan, in the Asia region.

How does Somnics make money?

Three revenue lines are on record. iNAP Sleep Therapy System (device + consumables) is the primary driver. The others are iNAP Essentials Subscription Program and lucira COVID-19 Test Kit Distribution.

Who are Somnics's main competitors?

Broad incumbents on record are ResMed, Philips Respironics and Fisher & Paykel Healthcare. Direct peers are Inspire Medical Systems, BMC Medical and Apex Medical. Emerging players are Oventus Medical, Natus Medical and Itamar Medical. Löwenstein Medical (LMT Korea partner) is listed as a regional player.

Does Somnics have an API?

No public API is recorded for Somnics.

What industry is Somnics in?

Somnics's product category is Sleep Apnea Therapy Medical Devices. Its primary akta.pro industry code is HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV), with a secondary code of HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals